German pharmaceutical company Stada plans a multi-billion-euro IPO in Frankfurt this autumn to reduce debt and provide an exit for its private equity owners.
US skips UN human rights review amid global criticism over concerns of politicization and selective bias.
Six mid-cap stocks show rising quarterly EPS, but caution is advised as not all profitable companies are poised for long-term success.
German pharmaceutical company Stada plans a multi-billion-euro IPO in Frankfurt this autumn to reduce debt and provide an exit for its private equity owners.
US skips UN human rights review amid global criticism over concerns of politicization and selective bias.
Six mid-cap stocks show rising quarterly EPS, but caution is advised as not all profitable companies are poised for long-term success.